Prinz, Marco; Schmidt, Hauke; Mildner, Alexander; Knobeloch, Klaus-Peter; Hanisch, Uwe-Karsten; Raasch, Jenni; Merkler, Doron; Detje, Claudia; Gutcher, Ilona; Mages, Jörg; Lang, Roland; Martin, Roland; Gold, Ralf; Becher, Burkhard; Brück, Wolfgang; Kalinke, Ulrich (2008). Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity, 28(5):675-686.
Full text not available from this repository.
The action of type I interferons in the central nervous system (CNS) during autoimmunity is largely unknown. Here, we demonstrate elevated interferon beta concentrations in the CNS, but not blood, of mice with experimental autoimmune encephalomyelitis (EAE), a model for CNS autoimmunity. Furthermore, mice devoid of the broadly expressed type I IFN receptor (IFNAR) developed exacerbated clinical disease accompanied by a markedly higher inflammation, demyelination, and lethality without shifting the T helper 17 (Th17) or Th1 cell immune response. Whereas adoptive transfer of encephalitogenic T cells led to enhanced disease in Ifnar1(-/-) mice, newly created conditional mice with B or T lymphocyte-specific IFNAR ablation showed normal EAE. The engagement of IFNAR on neuroectodermal CNS cells had no protective effect. In contrast, absence of IFNAR on myeloid cells led to severe disease with an enhanced effector phase and increased lethality, indicating a distinct protective function of type I IFNs during autoimmune inflammation of the CNS.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Hospital Zurich > Institute of Experimental Immunology|
|DDC:||570 Life sciences; biology|
610 Medicine & health
|Deposited On:||20 Jun 2012 09:25|
|Last Modified:||27 Nov 2013 21:24|
|Free access at:||Publisher DOI. An embargo period may apply.|
|Citations:||Web of Science®. Times cited: 120|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page